<DOC>
	<DOCNO>NCT02142153</DOCNO>
	<brief_summary>F901318 potent new antifungal agent treatment systemic fungal infection . This study test first time man objective assess safety , tolerability pharmacokinetic profile .</brief_summary>
	<brief_title>F901318 Single Ascending Dose Study Healthy Male Volunteers</brief_title>
	<detailed_description>Double blind , placebo control , ascend single intravenous dose , sequential group study . Forty subject study 5 cohort ( Groups A E ) , group consist 8 subject . Each subject study approximately 6 week . Each subject participate one treatment cohort , reside Clinical Research Unit ( CRU ) Day -1 ( day dose ) Day 6 ( 120 hour post-dose ) . Each cohort dose lead edge design two subject receive study drug ( 1 active 1 placebo ) first dose day , last 6 receive study drug ( active placebo ) second dosing day . All subject return post-study visit 8 10 day dose study medication . Cohorts dose 2 weekly interval . There review safety pharmacokinetic data prior dose escalation .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>1 . Subjects males ethnic origin 18 45 year age weigh 6090 kg inclusive 2 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) 3 . Subjects give write informed consent participate study abide study restriction 1 . Male subject , whose partner willing use appropriate contraception ( condom ) establish use oral , injected implant hormonal contraceptive , intrauterine device diaphragm spermicide three month last dose 2 . Subjects receive prescribed systemic topical medication within 14 day dose study drug unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day dose study drug ( exception vitamin/mineral supplement ) unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety 4 . Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day dose study drug unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety 5 . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical biological entity ) past 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>First man</keyword>
	<keyword>Antifungal</keyword>
	<keyword>Intravenous infusion</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>